Search Results - "van Biezen, A"

Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis by Stern, M, de Wreede, L C, Brand, R, van Biezen, A, Dreger, P, Mohty, M, de Witte, T M, Kröger, N, Ruutu, T

“…After allogeneic stem cell transplantation, graft-versus-host disease (GvHD) occurs through recognition of histocompatibility mismatches by donor T…”
Get full text

Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT by Ruutu, T, de Wreede, L C, van Biezen, A, Brand, R, Mohty, M, Dreger, P, Duarte, R, Peters, C, Garderet, L, Schönland, S, Gratwohl, A, Niederwieser, D, de Witte, T, Kröger, N

“…In patients treated with allogeneic stem cell transplantation (SCT) for malignant disease who suffer from a relapse after the transplantation, the role of…”
Get full text

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party by Sobh, M, Michallet, M, Gahrton, G, Iacobelli, S, van Biezen, A, Schönland, S, Petersen, E, Schaap, N, Bonifazi, F, Volin, L, Meijer, E, Niederwieser, D, El-Cheikh, J, Tabrizi, R, Fegeux, N, Finke, J, Bunjes, D, Cornelissen, J, Einsele, H, Bruno, B, Potter, M, Fanin, R, Mohty, M, Garderet, L, Kröger, N

“…We describe the use and outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for multiple myeloma (MM) in Europe between January 1990 and…”
Get full text

Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation by Ruutu, T, van Biezen, A, Hertenstein, B, Henseler, A, Garderet, L, Passweg, J, Mohty, M, Sureda, A, Niederwieser, D, Gratwohl, A, de Witte, T

“…Recommendations on indications for allogeneic haematopoietic SCT have been presented, but transplantation techniques remain poorly standardized. Pre-transplant…”
Get full text

Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT by Martino, R, de Wreede, L, Fiocco, M, van Biezen, A, von dem Borne, P A, Hamladji, R-M, Volin, L, Bornhäuser, M, Robin, M, Rocha, V, de Witte, T, Kröger, N, Mohty, M

“…In this multicenter retrospective study, the long-term outcomes of 878 adults with AML and refractory anemia with excess blasts (RAEB) with BM blasts <10% who…”
Get full text

Use of the quality management system "JACIE" and outcome after hematopoietic stem cell transplantation by Gratwohl, Alois, Brand, Ronald, McGrath, Eoin, van Biezen, Anja, Sureda, Anna, Ljungman, Per, Baldomero, Helen, Chabannon, Christian, Apperley, Jane

“…Competent authorities, healthcare payers and hospitals devote increasing resources to quality management systems but scientific analyses searching for an…”
Get full text

Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings by Kröger, N, Zabelina, T, de Wreede, L, Berger, J, Alchalby, H, van Biezen, A, Milpied, N, Volin, L, Mohty, M, Leblond, V, Blaise, D, Finke, J, Schaap, N, Robin, M, de Witte, T

“…We investigated whether a young human leukocyte antigen (HLA)-matched unrelated donor (MUD) should be preferred as donor to an HLA-identical sibling (MRD) for…”
Get full text

EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL) by Wiktor-Jedrzejczak, W., Drozd-Sokolowska, J., Eikema, D. J., Hoek, J., Potter, M., Wulf, G., Sellner, L., Ljungman, P., Chevallier, P., Volin, L., Koc, Y., Martin, S., Bunjes, D., Rovira, M., Itälä-Remes, M., Foá, R., Deconinck, E., Gedde-Dahl, T., Cornelissen, J., Collin, M., Brecht, A., Patel, A., de Groot, M., Reményi, P., Nagler, A., Finke, J., Turlure, P., Iacobelli, S., van Biezen, A., Schetelig, J., Kröger, N., Dreger, P.

“…Preliminary data suggest that allogeneic stem cell transplantation (allo-SCT) may be effective in T-prolymphocytic leukemia (T-PLL). The purpose of the present…”
Get full text

Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium by Wiktor-Jedrzejczak, W, Dearden, C, de Wreede, L, van Biezen, A, Brinch, L, Leblond, V, Brune, M, Volin, L, Kazmi, M, Nagler, A, Schetelig, J, de Witte, T, Dreger, P

“…T-prolymphocytic leukemia (T-PLL) has a very poor prognosis with conventional immunochemotherapy. Incidental reports suggest that allogeneic hematopoietic stem…”
Get full text

Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation by Schetelig, J, de Wreede, L C, van Gelder, M, Andersen, N S, Moreno, C, Vitek, A, Karas, M, Michallet, M, Machaczka, M, Gramatzki, M, Beelen, D, Finke, J, Delgado, J, Volin, L, Passweg, J, Dreger, P, Henseler, A, van Biezen, A, Bornhäuser, M, Schönland, S O, Kröger, N

“…For young patients with high-risk CLL, BTK-/PI3K-inhibitors or allogeneic stem cell transplantation (alloHCT) are considered. Patients with a low risk of…”
Get full text

Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation by Auner, H W, Szydlo, R, van Biezen, A, Iacobelli, S, Gahrton, G, Milpied, N, Volin, L, Janssen, J, Nguyen Quoc, S, Michallet, M, Schoemans, H, el Cheikh, J, Petersen, E, Guilhot, F, Schönland, S, Ahlberg, L, Morris, C, Garderet, L, de Witte, T, Kröger, N

“…Outcomes and prognostic factors of reduced intensity-conditioned allo-SCT (RIC allo-SCT) for multiple myeloma (MM) relapsing or progressing after prior…”
Get full text

Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT by Robin, M, Porcher, R, Zinke-Cerwenka, W, van Biezen, A, Volin, L, Mufti, G, Craddock, C, Finke, J, Richard, C, Passweg, J, Peniket, A, Maertens, J, Sucak, G, Gedde-Dahl, T, Vitek, A, Nagler, A, Blaise, D, Beelen, D, Maillard, N, Schwerdtfeger, R, de Witte, T, Kroger, N

“…We report a retrospective analysis of 246 myelodysplastic syndrome (MDS) patients in the EBMT (The European Society for Blood and Marrow Transplantation)…”
Get full text

Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia by van Gelder, M, de Wreede, L C, Schetelig, J, van Biezen, A, Volin, L, Maertens, J, Robin, M, Petersen, E, de Witte, T, Kröger, N

“…Treatment algorithms for poor cytogenetic-risk myelodysplastic syndrome (MDS), defined by chromosome 7 abnormalities or complex karyotype (CK), include…”
Get full text

Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party by Scheid, C, de Wreede, L, van Biezen, A, Koenecke, C, Göhring, G, Volin, L, Maertens, J, Finke, J, Passweg, J, Beelen, D, Cornelissen, J J, Itälä-Remes, M, Chevallier, P, Russell, N, Petersen, E, Milpied, N, Richard Espiga, C, Peniket, A, Sierra, J, Mufti, G, Crawley, C, Veelken, J H, Ljungman, P, Cahn, J Y, Alessandrino, E P, de Witte, T, Robin, M, Kröger, N

“…The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis. To validate…”
Get full text

The EBMT–ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis by Ruutu, T, Gratwohl, A, Niederwieser, D, de Witte, T, van der Werf, S, van Biezen, A, Mohty, M, Kröger, N, Rambaldi, A, McGrath, E, Sureda, A, Basak, G, Greinix, H, Duarte, R F

“…In 2013, recommendations for a standardized practice in the prophylaxis and treatment of GvHD were adopted and published by the European Society for Blood and…”
Get full text

Primary plasma cell leukemia and autologous stem cell transplantation by DRAKE, Mary B, IACOBELLI, Simona, VAN BIEZEN, Anja, MORRIS, Curly, APPERLEY, Jane F, NIEDERWIESER, Dietger, BJÖRKSTRAND, Bo, GAHRTON, Gösta

“…Primary plasma cell leukemia is a rare disorder accounting for less than 5% of malignant plasma cell diseases. It has a poor prognosis compared to multiple…”
Get full text

Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis by DREGER, P, BRAND, R, NIEDERWIESER, D, MILLIGAN, D, CORRADINI, P, FINKE, J, LAMBERTENGHI DELILIERS, G, MARTINO, R, RUSSELL, N, VAN BIEZEN, A, MICHALLET, M

“…To elucidate whether reduced-intensity conditioning (RIC) decreases treatment-related mortality (TRM) after allogeneic stem cell transplantation (allo-SCT) for…”
Get full text

Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT by Cremers, E. M. P., van Biezen, A., de Wreede, L. C., Scholten, M., Vitek, A., Finke, J., Platzbecker, U., Beelen, D., Schwerdtfeger, R., Volin, L., Harhalakis, N., Blijlevens, N., Nagler, A., Kröger, N., de Witte, T.

“…Many pre-transplant factors are known to influence the outcome of allogeneic stem cell transplantation (SCT) treatment in myelodysplastic syndromes (MDS)…”
Get full text

Efficacy and outcome of autologous transplantation in rare myelomas by MORRIS, Curly, DRAKE, Mary, NIEDERWIESER, Dietger, GAHRTON, Gosta, APPERLEY, Jane, LACOBELLI, Simona, VAN BIEZEN, Anja, BJORKSTRAND, Bo, GOLDSCHMIDT, Hartmut, HAROUSSEAU, Jean-Luc, MORGAN, Gareth, DE WITTE, Theo

“…As rare myelomas, i.e. the IgD, IgE, IgM and non-secretory forms, constitute only a small proportion of any study, relatively little is known about their…”
Get full text

Graft-versus-host driven graft-versus-leukemia effect of minor histocompatibility antigen HA-1 in chronic myeloid leukemia patients by Mutis, T, Brand, R, Gallardo, D, van Biezen, A, Niederwieser, D, Goulmy, E

Get full text